Topline results from the pivotal HAELO trial demonstrate that a single infusion of lonvo-z significantly reduces HAE attacks and the need for chronic prophylactic therapy.
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the U.S. Food and Drug Administration (FDA) has approved EKTERLY ® ...
Zacks Investment Research on MSN
NTLA falls 4% despite strong phase III HAE data, initiates rolling BLA
Shares of Intellia Therapeutics NTLA declined 4% on Monday despite positive top-line data from the global phase III HAELO ...
KalVista (KALV) to be acquired by Chiesi for $27/share: read why EKTERLY’s HAE growth, pediatric data, and key deal/approval ...
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a ...
Intellia Therapeutics’ CRISPR-based therapy lonvoguran ziclumeran reduced hereditary angioedema attacks by 87% in a pivotal phase 3 trial, meeting all primary and secondary endpoints. The one-time ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results